Form 4: GeneDx CFO Kevin Feeley Reports Routine Stock Transactions, Including RSU Vesting and Tax-Related Share Sale

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the acquisition of shares from restricted stock unit vesting and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), reported transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• On June 16, 2025, Mr. Feeley acquired 7,197 shares of Class A Common Stock through the settlement of RSUs, for which no consideration was paid.
• Concurrently, on June 16, 2025, Mr. Feeley sold 3,729 shares of Class A Common Stock at a price of $64.773 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the vesting and settlement of the RSUs and was not a discretionary transaction.
• Following these transactions, Mr. Feeley beneficially owns 8,769 shares of Class A Common Stock directly.
• Additionally, Mr. Feeley holds 50,378 Restricted Stock Units (RSUs) directly, which represent a contingent right to receive one share of Class A Common Stock per RSU upon settlement.
• The RSU vesting schedule involves 6.25% vesting in quarterly installments over a four-year period, commencing on March 16, 2023, contingent on continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports routine insider transactions related to executive compensation (RSU vesting and a tax-related share sale), which are expected and do not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The vesting of 7,197 Restricted Stock Units (RSUs) represents a form of compensation for the Chief Financial Officer, indicating continued alignment of management interests with shareholder value.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned, non-discretionary transaction, which can be viewed positively as it reduces concerns about opportunistic insider trading.

Negatives

• The sale of 3,729 shares, while for tax purposes, reduces the direct shareholding of the Chief Financial Officer by that amount.

Future Outlook

The document indicates that the remaining 50,378 Restricted Stock Units (RSUs) held by the Reporting Person will continue to vest in quarterly installments over a 4-year period commencing March 16, 2023, subject to continued service to the Issuer.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and a 'sell to cover' transaction for tax purposes. Such transactions are common across all industries for publicly traded companies and do not provide specific insights into broader industry trends or competitive dynamics within the genomics or diagnostics sector.

Related Party Transactions

• The acquisition of 7,197 shares through the settlement of Restricted Stock Units (RSUs) represents a form of compensation granted by the Issuer to its Chief Financial Officer, which is a related party transaction.

Stakeholder Impact

• Shareholders: The sale of shares by the CFO for tax purposes is a routine event and is unlikely to have a significant direct impact on the share price or shareholder value, especially given it was a pre-planned transaction.
• Employees: The RSU vesting demonstrates the company's compensation structure for executives, which may indirectly influence employee perception of equity compensation programs.

Next Steps

• Continued quarterly vesting of the remaining 50,378 Restricted Stock Units (RSUs) held by Kevin Feeley, subject to his continued service to GeneDx Holdings Corp.

Key Dates

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Share Sale, Tax Withholding, Executive Compensation, Kevin Feeley, Chief Financial Officer